TABLE 5.
Risk of cancer among levothyroxine users according to 3‐year average daily dose
| Cancer | Adjusted odds ratio a (95% CI) | P‐trend | ||
|---|---|---|---|---|
|
<0.34 DDD/day |
0.34‐≤0.67 DDD/day |
>0.67 DDD/day |
||
| Overall | 1.498 (1.406‐1.596) | 1.508 (1.453‐1.564) | 1.479 (1.381‐1.585) | <.0001** |
| Esophageal | 0.823 (0.379‐1.790) | 0.815 (0.502‐1.322) | 0.710 (0.272‐1.853) | .70 |
| Gastric | 0.990 (0.658‐1.489) | 1.263 (1.015‐1.570) | 1.181 (0.764‐1.824) | .17 |
| Colorectal | 1.314 (1.104‐1.564) | 1.120 (1.006‐1.247) | 1.021 (0.831‐1.256) | .003* |
| Liver | 1.185 (0.941‐1.493) | 0.933 (0.807‐1.078) | 0.922 (0.701‐1.214) | .005* |
| Pancreatic | 1.103 (0.665‐1.827) | 1.439 (1.085‐1.910) | 0.947 (0.524‐1.713) | .08 |
| Lung | 1.427 (1.174‐1.734) | 1.155 (1.021‐1.306) | 1.218 (0.965‐1.538) | <.0001** |
| Skin | 1.525 (1.052‐2.210) | 1.444 (1.122‐1.857) | 1.181 (0.715‐1.949) | .03 |
| Female breast | 1.463 (1.247‐1.716) | 1.189 (1.081‐1.308) | 1.157 (0.969‐1.382) | .0001** |
| Cervical | 1.117 (0.767‐1.628) | 0.730 (0.572‐0.930) | 0.445 (0.251‐0.789) | .01 |
| Prostate | 1.656 (1.210‐2.268) | 1.108 (0.867‐1.416) | 1.170 (0.770‐1.779) | .01 |
| Bladder | 1.275 (0.877‐1.853) | 1.084 (0.849‐1.383) | 1.716 (1.141‐2.580) | .03 |
| Kidney | 0.769 (0.476‐1.242) | 1.271 (0.989‐1.632) | 1.248 (0.743‐2.098) | .14 |
| Brain | 1.783 (0.944‐3.366) | 1.794 (1.313‐2.450) | 2.358 (1.392‐3.995) | <.0001** |
CI, confidence interval; DDD, defined daily dose.
a
Odds ratio adjusted for age, gender, comorbid conditions, age‐adjusted Charlson comorbidities index scores, and other drugs in Table 1.
*
P < .01; **P < .001.